Innovatus Capital Partners is a Investment Adviser And Portfolio Management Firm.
Business Model:
Revenue: $0
Employees: 0-0
Address: 777 Third Avenue
City: New York
State: NY
Zip: 10017
Country: US
Innovatus Capital Partners, they focus on both real and financial assets. Their firm&s;s investment in strategies that identifies distressed, disruptive, and growth opportunities.
Contact Phone:
+12126984580
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2019 | ConforMIS | Post-IPO Debt | 30M |
3/2022 | DNAnexus | Series H | 200M |
6/2022 | Eiger BioPharmaceuticals | Post-IPO Debt | 0 |
6/2022 | Eiger BioPharmaceuticals | Post-IPO Equity | 0 |
12/2019 | Akoya Biosciences | Equity | 50M |
12/2021 | Apollo Endosurgery | Post-IPO Debt | 35M |
8/2022 | JenaValve Technology | Series C | 0 |
7/2022 | Syapse | Growth | 35M |
11/2021 | Cala Health | Series D | 0 |
10/2021 | Exagen | Post-IPO Debt | 27.2M |
2/2019 | DNAnexus | Series F | 68M |
2/2021 | Personal Genome Diagnostics | Series C | 0 |
8/2022 | MDxHealth | Post-IPO Debt | 0 |
7/2021 | Imperative Care | Series D | 0 |
10/2018 | Personal Genome Diagnostics | Venture Round | 42M |
10/2017 | Exagen | Debt Financing | 25M |
9/2021 | Spacial | Seed Round | 3.5M |
11/2021 | Geneoscopy | Series B | 105M |
8/2022 | MDxHealth | Post-IPO Debt | 0 |
7/2022 | Syapse | Venture Round | 0 |
6/2022 | Eiger BioPharmaceuticals | Post-IPO Debt | 0 |
6/2022 | Eiger BioPharmaceuticals | Post-IPO Equity | 0 |
3/2022 | DNAnexus | Series H | 0 |
12/2021 | Apollo Endosurgery | Post-IPO Debt | 0 |
11/2021 | Cala Health | Series D | 0 |
11/2021 | Geneoscopy | Series B | 0 |
10/2021 | Exagen | Post-IPO Debt | 0 |
9/2021 | Spacial | Seed Round | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|